forumAdmin
04-01-2008, 07:22 PM
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that Biological Psychiatry published the results of a study showing VYVANSE? (lisdexamfetamine dimesylate), the first prodrug stimulant for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), provided significant efficacy in children for up to 12 hours.
External site More Info here... (http://www.medicalnewstoday.com/articles/90283.php)
Please return here to comment...............
External site More Info here... (http://www.medicalnewstoday.com/articles/90283.php)
Please return here to comment...............